ESMO 2023

Highlights in eBC

Preoperative checkpointinihition in ER+ disease

My highlights of ESMO23 in metastatic breast cancer

Remarkable efficacies in patients with HER2+ mBC with…

DATO-DX - where is it going?

Lu-PSMA leads forward

New 3rd line therapy for RCC

Clearing up non-clear cell RCC

Early use of enzalutamide in advanced prostate cancer

When the history of ADC is written: Redefining…

ALINA - immediate change of practice!

My highlights from ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Tarlatamab in SCLC

Amivantamab as a new SoC for EGFR Exon 20…

What was the most exciting news at ESMO23?

New and better biomarkers are needed!

What is your definition of triple-negative breast…

Anticipated updates and exciting new data for…

Detailed view of nodal-negative patients

ER-low corresponds diagnostically to ER-0 breast cancer

Pembrolizumab solidifies as SOC in early-stage TNBC

New data on neoadjuvant immunotherapy

Negative EFS results from NeoTrip

Metabolomics reveal differential expression of OMEGA 3…

Highlights in eBC

Carry-over effects in monarchE confirmed

Preoperative checkpointinihition in ER+ disease

Use of immunotherapy in the perioperative setting of…

Consolidation of data in early HR+ and triple-negative…

Clinically relevant effect of pembro also in PCR

Prognostic score in early HR+/HER2-BC: translational…

5 year follow-up

HR+ study with > 20 % PCR

MonarchE - trial update

Immunoncology in eBC - triple negative and more?

Our guidelines are correct

Ribociclib effective in all subtypes

Analysis of tumour microenvironment and…

Neoadjuvant IO - is their new strategy in HR+ breast…

Punti salienti in eBC

Nouvelles données sur l'immunothérapie néoadjuvante

MonarchE - mise à jour de l'essai

Studio NeoTrip: negativi i risultati

ADCs in HER2+, HER2low and TNBC - what is the future of…

How to organize a molecular tumorboards in breast…

New ADC for metastatic breast cancer?

Improvement of therapy outcome by app-based patient…

New targets, new linker, new ADCs - much more to learn…

OP seems to be dispensable for super responders

TULIP: Trastuzumab duocarmazine without OS benefit

HER2DX in the PHERgain trial

Our guidelines are correct

HS20089 - a novel ADC is coming for TNBC

Still on track for success in HER2-low MBC

T-DXd - new standard of care for brain mets?

Robust data from the monarchE

ADC + Immunotherapy - the BEGONIA study paradigm

Duvalumab + Dato-DXd effective

DATO-DX - where is it going?

TROP2 expression as a potential mechanism of resistance…

Patient-centered molecular medicine - a new approach

T-DXd also effective for brain metastases

Dato-DXd - new player in advanced luminal disease

Remarkable efficacies in patients with HER2+ mBC with…

Fulvestran better than anastrozole, but no survival…

Abemaciclib remains consistent in 5-year follow-up

Can surgery be spared following primary systemic…

New ADC in HR+ disease

Highlights in mBC

Benefit for SG even after intensive pretreatment

Improved oncological therapy with the smartphone

My highlights of ESMO23 in metastatic breast cancer

Even more new generation ADCs in breast cancer?

OP-1250 (Palezestrant) confirms the role of SIRDs after…

HER2DX en el estudio PHERgain

Lo studio BEGONIA nelle paziento con tumore triplo…

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par…

La expresión de TROP2 como potencial mecanismo de…

Punti salienti in mBC

HS20089 - un nuovo ADC che si affaccia sulla scenda del…

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym…

T-DXd - nowy standard postępowania w przerzutach do…

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

The optimal timing of RT after radical prostatectomy…

Targeted therapy will move forward - but more robust…

What is the future of immune therapy in prostate…

Longterm toxicity of adjuvant RT after prostatectomy

STAMPEDE. Bone prediction not for everyone - better…

RADICALS RT: Trial and controversies

EMBARK expands ENZA indication to PCa

IO therapy in metastatic prostate cancer.

PSMA FORE: Trial and controversies

Negative data for pembrolizumab in mHSCPC & mCRPC

EMBARK - Quality of Life

ENZA P:Trial and controversies

Lu-PSMA leads forward

Osteoprotection at mHSPC

Embark without fear

Salvage radiotherapy the new standard

Big data and AI prediction tools

When immunotherapy is probably not the best choice: The…

CXCR2 inhibitor in PCa

Precision medicine at mCRCP

Early use of enzalutamide in advanced prostate cancer

Immunotherapy in metastatic PCa

Combination of radioligand therapy with chemotherapy…

Brave New World in mCRPC

PSMAfore unleashes urooncologic opportunity

Cuando la inmunoterapia probablemente no es la mejor…

CXCR2 hämmare och prostatacancer

Immunterapi vid prostatacancer

STAMPEDE data. Skelettstärkande och riskstratifiering.

EMBARK och livskvalitet

Part 2: New standard of care in first line urothelial…

FGFR inhibitors and ADC combinations in urothelial…

Unique bladder delivery system of gemcitabine herolds…

Chemo-IO establishes itself in the first-line treatment…

The FGFR story in bladder cancer at ESMO23

FGFR inhibitors: What is the best scenario for this…

When the history of ADC is written: Redefining…

New SoC in firstline bladder cancer

DAD, DAD-IO

EV + Pembro as standard of care in first-line therapy…

Reescribiendo la historia de una enfermedad: Nuevo…

Inhibidores de FGFR: Cual es el mejor escenario para…

Στιγμιότυπα για τον καρκίνο των νεφρών και της…

Where does the future therapy go in renal cell…

Important new treatment option but only for subset of…

Belzutifan - whats next kidney cancer?

Belzutifan in later lines of therapy

Intermittent therapy also possible with TKIs

Clearing up non-clear cell RCC

Kidney cancer highlights at ESMO23

New mode of action in mRCC - ready for prime time?

ALINA - remarkably positive DFS in early-stage ALK+…

Neoadjuvant chemo-immunotherapy new standards in early…

Circulating DNA in AEGEAN trial

Scene is set for inductive immunotherapy

My highlights from ESMO 2023

ALINA - immediate change of practice!

Big improvements in early stage and a subset of…

Perioperative IO: OS-benefi from KEYNOTE-671

ALINA - a new paradigm in operated NSCLC with…

Substantial improvement in local regional NSCLC

Perioperativ immunotherapy for all resectable stage…

Perioperatieve chemo-immunotherapie voor alle patienten…

I miei punti salienti di ESMO 2023

Les points forts de l'ESMO 2023

ALINA - un nouveau paradigme dans cBNPC avec la fusion…

Activating EGFR-mutation - what's coming up?

Evolving landscape of ADCs

ESMO2023-impact on everyday practice!

Substantial improvement in rare alterations

Amivantamab at progression? MARIPOSA-2 trial

Practice changing results on exon 20 insertion mNSCLC

MARIPOSA: Trial and controversies

Changing treatment landscape in EGFR-mutated NSCLC

Big improvements in early stage and a subset of…

My highlights from ESMO 2023

PAPILLON - bringing together therapy for the 1st line

Adagrasib + pembrolizumab in patients with KRASG12C…

NRG fusions: a new drugable target?

Treatment sequences for EGFR-mutated Patients

Do ADCs have brain activity?

New standard of care for metastatic EGFR exon 20…

LIBRETO - a positive study, but was it necessary?

MARIPOSA II: Trial and controversies

Does immunotherapy still have a place in EGFR-positive…

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

By unanimous decision and still the champion –…

Amivantamab as a new SoC for EGFR Exon 20…

Amivantamab upfront? MARIPOSA trial

Brain metastases – options to improve the systemic…

Amivantamab at progression? MARIPOSA-2 trial

Veränderte Behandlungslandschaft bei EGFR-mutiertem…

Les points forts de l'ESMO 2023

Quelles séquences thérapeutiques pour les patients EGFR…

I miei punti salienti di ESMO 2023

L’amivantamab, nouveau standard de traitement pour les…

Gros progrès dans les traitments medicaeux des stades…

Amivantamab upfront? MARIPOSA trial

Heeft immunotherapie nog een plek in de behandeling van…

Nieuwe standaard voor gemetastaseerd EGFR exon20…

A new option in relapsed SCLC

New hope for patients with SCLC

Update on gynaecological cancers

Precision oncology in CUP

Evolution of the revolution - the RUBY trial

PCO Therapeutics

First data on luveltamab in multiline treatment for…

New data on sarkomas